⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

GB0139 (gb0139) | Accelerate Your Fibrosis Research

Home/Drugs/GB0139

GB0139

gb0139

Phase 2b

Sponsor: Galecto

Indication: IPF

Mechanism of Action

Galectin-3 inhibitor

Target: Galectin-3

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03832946

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase:PHASE2Org:Galecto Biotech AB

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

Inhibition of Galectin-3 Expression Could Preserve the Immunoregulatory Function of Mesenchymal Stem Cells During Cell Passaging.

Wang M, Jiang Y, Wan J et al.

Front Biosci (Landmark Ed)2025 Aug 27

Binding free energy analysis of galectin-3 natural ligands and synthetic inhibitors.

Newman L, Vaissier Welborn V

Protein Sci2025 Jun

Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy.

Liu H, Hwang SY, Lee SS

Pharmaceuticals (Basel)2023 Jul 7

Novel inhibitory effect of galectin-3 on the respiratory burst induced by Staphylococcus aureus in human neutrophils.

Validated Models

This drug has been validated in the following preclinical models:

Venkatakrishnan V, Elmwall J, Lahiri T et al.

Glycobiology2023 Jun 21

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.

Zetterberg FR, MacKinnon A, Brimert T et al.

J Med Chem2022 Oct 13

View more on PubMed